The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters
et al., bioRxiv, doi:10.1101/2022.02.08.479634 (Preprint)
, The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian.., bioRxiv, doi:10.1101/2022.02.08.479634 (Preprint)
In Vitro study showing that nitazoxanide inhibits SARS-CoV-2 in H9, iAT2, Vero E6, Vero TMPRSS2, and Ace2-A549 cells.Syrian hamster study showing improvements in SARS-CoV-2 related weight loss, inflammation, viral load, and lung synctia formation with nitazoxanide.
Miorin et al., 9 Feb 2022, preprint, 35 authors.
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2022.02.08.479634; this version posted February 9, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
1
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates
disease pathogenesis in Syrian hamsters
2
3
4
5
6
§Lisa Miorin1,2,#, Chad E. Mire3,#, Shahin Ranjbar4,#,
7
Adam J. Hume5,6, Jessie Huang7,8, Nicholas A. Crossland5,9, Kris M White1,2, Manon Laporte1,2,
8
Thomas Kehrer1,2, Viraga Haridas4, Elena Moreno1,2, Aya Nambu4, Sonia Jangra1,2,
9
Anastasija Cupic1,2, Marion Dejosez10, Kristine A. Abo7,8, Anna E. Tseng5,9,
10
Rhiannon B. Werder7,8, Raveen Rathnasinghe1,2, Tinaye Mutetwa1, Irene Ramos1,
11
Julio Sainz de Aja11, Carolina Garcia de Alba Rivas11, Michael Schotsaert1,2, Ronald B. Corley5,9,
12
James V. Falvo4, Ana Fernandez-Sesma1, Carla Kim11,12,13, Jean-François Rossignol14,
13
Andrew A. Wilson7,8, Thomas Zwaka10, Darrell N. Kotton7,8,9, Elke Mühlberger5,6,
14
Adolfo García-Sastre1,2,15,16,17, §Anne E. Goldfeld4,18,19
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
1
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Global Health
Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3University
of Texas Medical Branch, Galveston, TX, USA; 4Program in Cellular and Molecular Medicine, Boston
Children’s Hospital, Harvard Medical School, Boston, MA, USA; 5National Emerging Infectious Diseases
Laboratories, Boston University, Boston, MA, USA 6Department of Microbiology, Boston University School
of Medicine, Boston, MA, USA; 7Center for Regenerative Medicine of Boston University and Boston Medical
Center, Boston, MA, USA; 8The Pulmonary Center and Department of Medicine, Boston University School
of Medicine, Boston, MA, USA; 9Department of Pathology and Laboratory Medicine, Boston University
School of Medicine, Boston, MA, USA; 10Cell, Developmental & Regenerative Biology, Icahn School of
Medicine at Mount Sinai; New York, NY, USA; 11Stem Cell Program, Boston Children’s Hospital, Boston,
MA, USA; 12Harvard Stem Cell Institute, Cambridge, Massachusetts; 13Department of Genetics, Harvard
Medical School, Boston, MA, USA; 14Romark Institute for Medical Research, Tampa, FL, USA;15Department
of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
16
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 17Department of
Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,
USA; 18Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, USA; 19Department of Immunology and Infectious Diseases, Harvard T.C.
Chan School of Public Health, Boston, MA, USA.
36
#These authors contributed equally
37
§To whom correspondence should be addressed:
38
Lisa Miorin: lisa.miorin@mssm.edu; Anne E. Goldfeld: anne.goldfeld@childrens.harvard.edu
39
bioRxiv preprint doi: https://doi.org/10.1101/2022.02.08.479634; this version posted February 9, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
40
Abstract
41
42
A well-tolerated and cost-effective oral drug that..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.